Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of BIO89-100 in NASH with Compensated Cirrhosis
NCT05022693Phase 1Completed
- Sponsor
- 89bio
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegozafermin in Nonalcoholic steatohepatitis (NASH), sponsored by 89bio. Primary endpoint: Pharmacokinetic Profile of liquid formulation of BIO89-100 at 22 days. Started Aug 2021; status: completed.
02
Drugs
pegozafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05022693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05022693.